Cargando…

Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism

PPARγ (peroxisome proliferator activated receptor γ) is a ligand activated transcription factor of the nuclear receptor superfamily that controls the expression of a variety of genes involved in fatty acid metabolism, adipogenesis, and insulin sensitivity. While endogenous ligands of PPARγ include f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroker, Alice J., Bruning, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578752/ https://www.ncbi.nlm.nih.gov/pubmed/26435709 http://dx.doi.org/10.1155/2015/816856

Ejemplares similares

A structural mechanism for directing corepressor-selective inverse agonism of PPARγ
por: Brust, Richard, et al.
Publicado: (2018)

Structural and Dynamic Elucidation of a Non-acid PPARγ Partial Agonist: SR1988
por: Frkic, Rebecca L., et al.
Publicado: (2018)

Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism
por: Lizcano, Fernando, et al.
Publicado: (2013)

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
por: Samuelsson, O., et al.
Publicado: (2013)

Oxaliplatin Neurotoxicity Involves Peroxisome Alterations. PPARγ Agonism as Preventive Pharmacological Approach
por: Zanardelli, Matteo, et al.
Publicado: (2014)

Divergent Mechanisms for PPARγ Agonism in Ameliorating Aging-Related Versus Cranial Irradiation-Induced Context Discrimination Deficits
por: Cortez, Ibdanelo, et al.
Publicado: (2019)

Mechanism of partial agonism in AMPA-type glutamate receptors
por: Salazar, Hector, et al.
Publicado: (2017)

Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
por: Boeckmans, Joost, et al.
Publicado: (2019)

PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
por: Perreault, Mylène, et al.
Publicado: (2008)

Atractylodin Ameliorates Colitis via PPARα Agonism
por: Heo, Gwangbeom, et al.
Publicado: (2023)

Novel derivatives of eugenol as potent anti-inflammatory agents via PPARγ agonism: rational design, synthesis, analysis, PPARγ protein binding assay and computational studies
por: Anjum, Noor Fathima, et al.
Publicado: (2022)

The therapeutic potential of inhibiting PPARγ phosphorylation to treat type 2 diabetes
por: Frkic, Rebecca L., et al.
Publicado: (2021)

Structural Mechanism of N-Methyl-D-Aspartate Receptor Type 1 Partial Agonism
por: Ylilauri, Mikko, et al.
Publicado: (2012)

Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARγ agonism
por: Nenov, Miroslav N., et al.
Publicado: (2014)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
por: Tenenbaum, Alexander, et al.
Publicado: (2005)

Biased versus Partial Agonism in the Search for Safer Opioid Analgesics
por: Azevedo Neto, Joaquim, et al.
Publicado: (2020)

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

The Regulatory Roles of PPARs in Skeletal Muscle Fuel Metabolism and Inflammation: Impact of PPAR Agonism on Muscle in Chronic Disease, Contraction and Sepsis
por: Crossland, Hannah, et al.
Publicado: (2021)

Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease
por: Katkar, Gajanan D., et al.
Publicado: (2022)

Kinetic basis of partial agonism at NMDA receptors
por: Kussius, Cassandra L, et al.
Publicado: (2009)

Pharmacological Repression of PPARγ Promotes Osteogenesis
por: Marciano, David P., et al.
Publicado: (2015)

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
por: Ballav, Sangeeta, et al.
Publicado: (2022)

The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy
por: Ericsson, Anette, et al.
Publicado: (2017)

Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model
por: Cortez, IbDanelo, et al.
Publicado: (2020)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

Mechanistic origin of partial agonism of tetrahydrocannabinol for cannabinoid receptors
por: Dutta, Soumajit, et al.
Publicado: (2022)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
por: Ayza, Muluken Altaye, et al.
Publicado: (2020)

PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix
por: Frkic, Rebecca L., et al.
Publicado: (2018)

PPARγ in Neuroblastoma
por: Peri, Alessandro, et al.
Publicado: (2008)

Biased agonism
por: Kenakin, Terry
Publicado: (2009)

A structural mechanism of nuclear receptor biased agonism
por: Nemetchek, Michelle D., et al.
Publicado: (2022)

Aripiprazole, A Drug that Displays Partial Agonism and Functional  Selectivity
por: Tuplin, Erin W., et al.
Publicado: (2017)

Muscle-Specific PPAR [Formula: see text] Agonism May Provide Synergistic Benefits with Life Style Modifications
por: Erol, Adnan
Publicado: (2007)

PPARγ and Cognitive Performance
por: d’Angelo, Michele, et al.
Publicado: (2019)

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
por: Campbell, Jonathan E.
Publicado: (2020)

PPARγ and Apoptosis in Cancer
por: Elrod, Heath A., et al.
Publicado: (2008)

Nutraceuticals as Ligands of PPARγ
por: Penumetcha, Meera, et al.
Publicado: (2012)

Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer's Disease
por: Govindarajulu, Manoj, et al.
Publicado: (2018)

A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes
por: Michel, Martin C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_49ckvkq8eadkh7tuv702rvhrh3